Literature DB >> 17846245

Histopathologic evidence of capecitabine corneal toxicity in dogs.

M Zarfoss1, E Bentley, M Milovancev, C Schmiedt, R Dubielzig, J McAnulty.   

Abstract

In an experimental model of transplant rejection, renal transplants were performed on 6 mixed-breed dogs. Capecitabine (CPC) was administered as an oral immunosuppressive agent. All recipients received systemic CPC, cyclosporine (CSA), prednisolone, and famotidine throughout the study. Two dogs developed superficial keratitis, which was characterized by multifocal geographic erosions, superficial corneal epithelial pigmentation, and corneal neovascularization. These clinical signs correlated with the dose of CPC given, whereas other drug doses remained unchanged. After euthanasia, routine histologic sections were stained with hematoxylin and eosin and with alcian blue periodic acid-Schiff for light microscopic evaluation. Ocular histopathologic abnormalities were limited to neovascularization and inflammatory infiltrate of the anterior corneal stroma and abnormal basal cell morphology, disorganization, thinning, and pigmentation of the corneal epithelium. The purpose of this communication is to describe the clinical and histopathologic evidence of CPC corneal toxicity in dogs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846245     DOI: 10.1354/vp.44-5-700

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  2 in total

1.  Treatment of Capecitabine Corneal Side Effects With Autologous Blood-derived Serum Eye Drops.

Authors:  Federico DI Staso; Irene Gattazzo; Beatrice Taurelli Salimbeni; Alessandro Lambiase; Gianluca Scuderi; Silvio DI Staso; Marco Ciancaglini
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

2.  Use of oral paclitaxel for the treatment of bladder tumors in dogs.

Authors:  Hyung-Kyu Chae; Ji-In Yang; Ju-Hyun An; In-Hyun Lee; Min-Hee Son; Woo-Jin Song; Hwa-Young Youn
Journal:  J Vet Med Sci       Date:  2020-04-03       Impact factor: 1.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.